Navigation Links
Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
Date:10/7/2008

the treatment of celiac disease and IBD.

The third poster presentation, "Relevance of the Gastrointestinal Symptom Rating Scale (GSRS) in Patients with Celiac Disease" (Poster 1023), includes results from a qualitative study conducted to investigate the validity of the GSRS in patients with celiac disease and to explore if the GSRS would constitute an appropriate and relevant scale to demonstrating the efficacy of novel treatments for celiac disease. Results showed that relevant subscales of the GSRS may be useful in clinical trials of novel treatments for celiac disease.

About Celiac Disease

Celiac disease (CD) is an inherited, lifelong T-cell mediated auto-immune disorder where the environmental trigger has been identified as gluten, which is found in wheat, barley, and rye. It is characterized by small intestinal inflammation and injury. CD is a growing public health concern, affecting approximately 3 million people in the United States and over 6.5 million people worldwide. The ingestion of gluten causes an immune response which triggers an inflammatory reaction in the small intestine. This then causes damage to the villi in the small intestine and can lead to total villous atrophy in CD. This results in varying symptoms such as fatigue, skin rash, anemia, fertility issues, stillborn births, joint pain, weight loss, pale sores inside the mouth, tooth discoloration or loss of enamel, depression, chronic diarrhea or constipation, and abdominal pain and bloating. The immunology and nutritional abnormalities in celiac disease can potentially result in long-term complications such as osteoporosis, refractory sprue, small intestinal cancer, and lymphoma. The only current management of CD is complete elimination of gluten from the diet, which can be very difficult to implement in practice.

About "Larazotide Acetate"

Larazotide acetate is an experimental medicine and an inhibitor of barrier dysfunction that has been shown to block abno
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
2. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
3. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
4. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
5. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
6. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
7. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
10. Tobira Therapeutics Inc. Receives US Patent for TBR-652
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Verathon®, maker of BladderScan® bladder volume instruments ... volume ultrasound is now included in the ... of Catheter-Associated Urinary Tract Infections (CA-UTIs). ... November 2009, replace the previous guidelines which ... are located on the Web at: ...
(Date:12/16/2009)... Greenway Medical Technologies, Inc. today announced that its ... management and interoperability solution, Prime Suite® 2011, ... annual 2009 Top 20 Best in KLAS ... ,, For practices having between six and 25 ... in KLAS in ambulatory EMR for the fourth ...
(Date:12/16/2009)... -- BioSpecifics Technologies Corp. (Nasdaq: BSTC ), ... products, today announced top-line efficacy and safety results ... for the treatment of Peyronie,s disease. Peyronie,s disease ... on the shaft of the penis, which can ... or impossible in advanced cases. The Phase 2b ...
Breaking Medicine Technology:New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 2New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 4New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 5Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4Dutch Top Institute Pharma Attracts International Interest 56710 1Dutch Top Institute Pharma Attracts International Interest 56710 2Cell Therapeutics Inc 28CTI 29 to Present at BioCenturys NewsMakers in the Biotech Industry Conference 13959 1Oxygen Biotherapeutics Inc Posts Latest Blog by CEO Chris Stern 56708 1
... DIEGO, May 21, 2007 /PRNewswire/ -- Asenapine -- ... business unit of Akzo Nobel, for bipolar I ... effective than placebo,in treating acute manic and mixed ... Phase III results, from a study,presented at the ...
... Data Presented at 2007 APA Meeting -, ... Data,from four new studies examining safety and ... being studied as a potential treatment for ... today at the,2007 American Psychiatric Association annual ...
Other Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8
(Date:12/16/2009)... WASHINGTON The omega-3 essential fatty acids commonly ... avoid sensory overload, according to research published by ... omega-3s to the information-processing problems found in people ... Huntington,s disease; and other afflictions of the nervous ... journal Behavioral Neuroscience , provides more evidence ...
(Date:12/16/2009)... of Digital Pen and Paper technology and the provider of ... announced that it is ranked among the Fastest Growing Technology ... , ... (PRWEB) December 16, 2009 ... the capture, digitalization and management of handwritten data. Kayentis targets ...
(Date:12/16/2009)... at all-time low, government report shows, , , WEDNESDAY, Dec. ... United States has reached almost 78 years, a record ... in 2007, women can expect to live to 80.4 ... to the report from the U.S. Centers for Disease ... can expect to live longer than their parents, life ...
(Date:12/16/2009)... FRESNO, Calif., Dec. 16 New ... that bioactive compounds in pistachios, and molecules ... ,, Pistachio oil decreases levels of an ... with tetratricopeptide repeats 2). Inflammation is a ... damaged cells or irritants, and it underlies ...
(Date:12/16/2009)... of diagnostic procedures in cardiology. The idea of publishing ... expertise of European cardiovascular imagers, is therefore long awaited. ... written with a patient rather than technology-based approach, helping ... the aid of imaging. , The book is ... and practice of cardiac imaging and its clinical use ...
Breaking Medicine News(10 mins):Health News:New study links DHA type of omega-3 to better nervous-system function 2Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3
... the tissue abnormalities, or lesions, that typically precede cervical ... genotypes// of the human papillomavirus (HPV) than previously reported, ... of Cancer Epidemiology, Biomarkers & Prevention. ,Although ... opening to the womb can harbor multiple HPV types, ...
... Medical Center is among 10 institutions selected to oversee ... critical trauma// and sudden cardiac arrest. ,The ... and Canadian agencies to fund the $50 million Resuscitation ... in 10 North American regions. ,The centers ...
... battle super bugs, including MRSA, has found its way to ... as Tygacil, is one of the few new antibiotics to ... ,Micro organisms have undergone mutations that enabled them ... infections, such as MRSA, in hospitals. ,The new ...
... the human brain to enhance memories like the ability to ... previous studies had established the benefits of sleep for non-declarative ... on a keyboard. It was explained that the new experiment ... the facts for a test, where in the brain's hippocampus ...
... Medical Sciences (MIMS) is planning to launch a chain of ... a group of non-resident Indian (NRI) doctors residing in Gulf ... land in Kottakal in Malappuram district of the state for ... newspaper. ,MIMS chairman Azad Moopen told the newspaper ...
... Safety Authority (NZFSA) has warned people against consuming uncooked ... clearly labelled as requiring to be cooked before consuming. ... to sometimes carry norovirus, which causes a gastrointestinal illness. ... are packed frozen in 1kg bags and labeled according ...
Other Medicine News:Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 2Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 3Health News:Medical Center to Test Methods of Improving Cardiac Arrest, Trauma Survival 2Health News:New Drugs To Combat Mutant Bugs 2Health News:Sleep Essential For A Strong Memory 2
... an extra-high transmission rate, especially in ... to the CFI plan Achromat series, ... observation and photomicrography. Because of ... as multipurpose objectives for brightfield, fluorescence, ...
Zeiss offers a full range of filter sets for a variety of applications....
... exceptional quality for this class of objectives. ... dramatically improved with performance similar to the ... also corrected for spherical aberration and provide ... of view. The DL phase contrast objectives ...
... superb field flatness, high UV transmission ... extra long working distances, these objectives ... with inverted microscopes. Because of their ... ELWD DM,objectives can be used universally ...
Medicine Products: